Skip to main content

Cesar Jimenez Hernandez

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Cesar Jimenez Hernandez

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Malalties hepàtiques

IP: Joan Genescà Ferrer
Collaborators: Beatriz Minguez Rosique, Sergi Colomer Castell, Elena Vargas Accarino, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Victor Manuel Vargas Blasco, Maria Buti Ferret, Montserrat Gomez Perez, Maria Margarita Torrens Buscató, Judit Vico Romero, Josep Quer Sivila, Anna Feliu Prius, Adriana Palom Agusti, Juan Manuel Pericàs Pulido, Maria Martell Pérez-Alcalde, Damir Garcia Cehic, Laura Puente Ramo, Isabel Campos Varela, María Bermúdez Ramos, Juan Ignacio Esteban Mur, Ester Palacio Gutierrez, Susana Anton Calvo, Monica Higuera Urbano, Elena de Sena Fernández, Meritxell Ventura Cots, Cristina Adame Castillo, Meritxell Llorens Revull, Emma Bigas Alsina, Judit Vidal Gonzalez, Carolina Campos Martinez, Macarena Simon-Talero Horga, Jesus Manuel Rivera Esteban, David Tabernero Caellas, Mònica Pons Delgado, Marcella Salzano , Cesar Jimenez Hernandez, Laura Cecconi , Ramiro Manzano Nuñez
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 60000
Reference: 2021 SGR 00462
Duration: 01/01/2022 - 31/12/2024

LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

IP: Victor Manuel Vargas Blasco
Collaborators: Ester Palacio Gutierrez, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Cesar Jimenez Hernandez
Funding agency: EUROPEAN COMMISSION
Funding: 409557
Reference: LIVERHOPE_H2020RTD2016
Duration: 01/01/2017 - 28/02/2023

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. GRANT AGREEMENT NO: 634579

IP: Victor Manuel Vargas Blasco
Collaborators: Alejandro López Targa, Cesar Jimenez Hernandez
Funding agency: EUROPEAN COMMISSION
Funding: 93750
Reference: CARBALIVE_H2020-PHC2014
Duration: 01/05/2015 - 31/01/2021

Related news

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

The book is the culmination of the last ten years of research by Dr Gregori, Dr Quer and Dr Rodríguez-Frías in the Viral Hepatitis laboratory

This new method improves and streamlines drug development processes

Related professionals

Viena Gaza Solé

Viena Gaza Solé

Tècnic de Recerca - Grau Mig
Quality, Processes and Document Management
Digital Transformation and Quality Area
Read more
Milagros Mejia

Milagros Mejia

Administration and Management
Cardiovascular Diseases
Read more
Sanae El Bouhali El Mallem

Sanae El Bouhali El Mallem

Tècnic/a Grau Superior
National Projects Unit
Competitive Projects Area
Read more
Mercedes Pérez Lafuente

Mercedes Pérez Lafuente

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.